{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:37:17Z","timestamp":1740109037677,"version":"3.37.3"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T00:00:00Z","timestamp":1509321600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00345-017-2107-4","type":"journal-article","created":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T06:37:01Z","timestamp":1509345421000},"page":"149-151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked?"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5107-3523","authenticated-orcid":false,"given":"Igor","family":"Tsaur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik","family":"Borgmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian I.","family":"Surcel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,30]]},"reference":[{"key":"2107_CR1","doi-asserted-by":"crossref","unstructured":"Taplin M-E, Antonarakis ES, Ferrante KJ, Horgan K, Blumenstein BA, Saad F, Luo J, De Bono JS (2017) Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7\u00a0+\u00a0metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 35:(suppl; abstr 5005)","DOI":"10.1200\/JCO.2017.35.15_suppl.5005"},{"key":"2107_CR2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:1028\u20131038","journal-title":"N Engl J Med"},{"key":"2107_CR3","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaoncol.2015.1341","volume":"1","author":"ES Antonarakis","year":"2015","unstructured":"Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J (2015) Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol 1:582\u2013591","journal-title":"JAMA Oncol"},{"key":"2107_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2016.07.021","volume":"71","author":"C Bernemann","year":"2017","unstructured":"Bernemann C, Schnoeller TJ, Luedeke M, Steinestel K, Boegemann M, Schrader AJ, Steinestel J (2017) Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castration resistant prostate cancer. Eur Urol 71:1\u20133","journal-title":"Eur Urol"},{"key":"2107_CR5","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/1078-0432.CCR-16-1070","volume":"23","author":"F Qu","year":"2017","unstructured":"Qu F, Xie W, Nakabayashi M, Zhang H, Jeong SH, Wang X, Komura K, Sweeney CJ, Sartor O, Lee GM, Kantoff PW (2017) Association of AR-V7 and prostate-specific antigen rna levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer. Clin Cancer Res 23:726\u2013734","journal-title":"Clin Cancer Res"},{"key":"2107_CR6","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.eururo.2016.11.024","volume":"71","author":"HI Scher","year":"2017","unstructured":"Scher HI, Graf RP, Schreiber NA, McLaughlin B, Lu D, Louw J, Danila DC, Dugan L, Johnson A, Heller G, Fleisher M, Dittamore R (2017) Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer. Eur Urol 71:874\u2013882","journal-title":"Eur Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-017-2107-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-017-2107-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-017-2107-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T05:42:30Z","timestamp":1570254150000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-017-2107-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,30]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["2107"],"URL":"https:\/\/doi.org\/10.1007\/s00345-017-2107-4","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"type":"print","value":"0724-4983"},{"type":"electronic","value":"1433-8726"}],"subject":[],"published":{"date-parts":[[2017,10,30]]}}}